《医疗机构处方审核规范》印发:含中成药处方需审核相互作用和配伍禁忌

2018-07-13 黄 蓓 中国中医

国家卫生健康委、国家中医药管理局、中央军委后勤保障部办公厅联合印发《医疗机构处方审核规范》,对处方审核的基本要求、审核依据和流程、审核内容、审核质量管理、培训等作出规定,明确药师是处方审核工作的第一责任人,所有处方均应当经审核通过后方可进入划价收费和调配环节,未经审核通过的处方不得收费和调配。

国家卫生健康委、国家中医药管理局、中央军委后勤保障部办公厅联合印发《医疗机构处方审核规范》,对处方审核的基本要求、审核依据和流程、审核内容、审核质量管理、培训等作出规定,明确药师是处方审核工作的第一责任人,所有处方均应当经审核通过后方可进入划价收费和调配环节,未经审核通过的处方不得收费和调配。

《规范》对适宜性审核做出要求,明确对于西药和中成药处方,应审核处方中的西药、中成药、中成药与西药、中成药与中药饮片之间是否存在重复给药和相互作用,是否存在配伍禁忌。对于中药饮片处方,应当审核中药饮片处方用药与中医诊断是否相符;饮片的名称、炮制品选用是否正确,煎法、用法、脚注等是否完整、准确;毒麻贵细饮片是否按规定开方;特殊人群如儿童、老年人、孕妇及哺乳期妇女、脏器功能不全患者用药是否有禁忌使用的药物等。

二级以上医院、妇幼保健院和专科疾病防治机构应当按照《规范》执行,其他医疗机构参照执行。

第一章  总则

第一条 为规范医疗机构处方审核工作,促进合理用药,保障患者用药安全,根据《中华人民共和国药品管理法》《医疗机构药事管理规定》《处方管理办法》《医院处方点评管理规范(试行)》等有关法律法规、规章制度,制定本规范。

第二条 处方审核是指药学专业技术人员运用专业知识与实践技能,根据相关法律法规、规章制度与技术规范等,对医师在诊疗活动中为患者开具的处方,进行合法性、规范性和适宜性审核,并作出是否同意调配发药决定的药学技术服务。

审核的处方包括纸质处方、电子处方和医疗机构病区用药医嘱单。

第三条 二级以上医院、妇幼保健院和专科疾病防治机构应当按照本规范执行,其他医疗机构参照执行。

第二章  基本要求

第四条 所有处方均应当经审核通过后方可进入划价收费和调配环节,未经审核通过的处方不得收费和调配。

第五条 从事处方审核的药学专业技术人员(以下简称药师)应当满足以下条件:

(一)取得药师及以上药学专业技术职务任职资格。

(二)具有3年及以上门急诊或病区处方调剂工作经验,接受过处方审核相应岗位的专业知识培训并考核合格。

第六条 药师是处方审核工作的第一责任人。药师应当对处方各项内容进行逐一审核。医疗机构可以通过相关信息系统辅助药师开展处方审核。对信息系统筛选出的不合理处方及信息系统不能审核的部分,应当由药师进行人工审核。

第七条 经药师审核后,认为存在用药不适宜时,应当告知处方医师,建议其修改或者重新开具处方;药师发现不合理用药,处方医师不同意修改时,药师应当作好记录并纳入处方点评;药师发现严重不合理用药或者用药错误时,应当拒绝调配,及时告知处方医师并记录,按照有关规定报告。

第八条 医疗机构应当积极推进处方审核信息化,通过信息系统为处方审核提供必要的信息,如电子处方,以及医学相关检查、检验学资料、现病史、既往史、用药史、过敏史等电子病历信息。信息系统内置审方规则应当由医疗机构制定或经医疗机构审核确认,并有明确的临床用药依据来源。

第九条 医疗机构应当制定信息系统相关的安全保密制度,防止药品、患者用药等信息泄露,做好相应的信息系统故障应急预案。

第三章  审核依据和流程

第十条 处方审核常用临床用药依据:国家药品管理相关法律法规和规范性文件,临床诊疗规范、指南,临床路径,药品说明书,国家处方集等。

第十一条 医疗机构可以结合实际,由药事管理与药物治疗学委员会充分考虑患者用药安全性、有效性、经济性、依从性等综合因素,参考专业学(协)会及临床专家认可的临床规范、指南等,制订适合本机构的临床用药规范、指南,为处方审核提供依据。

第十二条 处方审核流程:

(一)药师接收待审核处方,对处方进行合法性、规范性、适宜性审核。

(二)若经审核判定为合理处方,药师在纸质处方上手写签名(或加盖专用印章)、在电子处方上进行电子签名,处方经药师签名后进入收费和调配环节。

(三)若经审核判定为不合理处方,由药师负责联系处方医师,请其确认或重新开具处方,并再次进入处方审核流程。

第四章 审核内容

第十三条 合法性审核。

(一)处方开具人是否根据《执业医师法》取得医师资格,并执业注册。

(二)处方开具时,处方医师是否根据《处方管理办法》在执业地点取得处方权。

(三)麻醉药品、第一类精神药品、医疗用毒性药品、放射性药品、抗菌药物等药品处方,是否由具有相应处方权的医师开具。

第十四条 规范性审核。

(一)处方是否符合规定的标准和格式,处方医师签名或加盖的专用签章有无备案,电子处方是否有处方医师的电子签名。

(二)处方前记、正文和后记是否符合《处方管理办法》等有关规定,文字是否正确、清晰、完整。

(三)条目是否规范。

1.年龄应当为实足年龄,新生儿、婴幼儿应当写日、月龄,必要时要注明体重;

2.中药饮片、中药注射剂要单独开具处方;

3.开具西药、中成药处方,每一种药品应当另起一行,每张处方不得超过5种药品;

4.药品名称应当使用经药品监督管理部门批准并公布的药品通用名称、新活性化合物的专利药品名称和复方制剂药品名称,或使用由原卫生部公布的药品习惯名称;医院制剂应当使用药品监督管理部门正式批准的名称;

5.药品剂量、规格、用法、用量准确清楚,符合《处方管理办法》规定,不得使用“遵医嘱”“自用”等含糊不清字句;

6.普通药品处方量及处方效期符合《处方管理办法》的规定,抗菌药物、麻醉药品、精神药品、医疗用毒性药品、放射药品、易制毒化学品等的使用符合相关管理规定;

7.中药饮片、中成药的处方书写应当符合《中药处方格式及书写规范》。

第十五条 适宜性审核。

(一)西药及中成药处方,应当审核以下项目:

1.处方用药与诊断是否相符;

2.规定必须做皮试的药品,是否注明过敏试验及结果的判定;

3.处方剂量、用法是否正确,单次处方总量是否符合规定;

4.选用剂型与给药途径是否适宜;

5.是否有重复给药和相互作用情况,包括西药、中成药、中成药与西药、中成药与中药饮片之间是否存在重复给药和有临床意义的相互作用;

6.是否存在配伍禁忌;

7.是否有用药禁忌:儿童、老年人、孕妇及哺乳期妇女、脏器功能不全患者用药是否有禁忌使用的药物,患者用药是否有食物及药物过敏史禁忌证、诊断禁忌证、疾病史禁忌证与性别禁忌证;

8.溶媒的选择、用法用量是否适宜,静脉输注的药品给药速度是否适宜;

9.是否存在其他用药不适宜情况。

(二)中药饮片处方,应当审核以下项目:

1.中药饮片处方用药与中医诊断(病名和证型)是否相符;

2.饮片的名称、炮制品选用是否正确,煎法、用法、脚注等是否完整、准确;

3.毒麻贵细饮片是否按规定开方;

4.特殊人群如儿童、老年人、孕妇及哺乳期妇女、脏器功能不全患者用药是否有禁忌使用的药物;

5. 是否存在其他用药不适宜情况。

第五章 审核质量管理

第十六条 处方审核质量管理以自我监测评价为主,以行政部门干预评价为辅。

医疗机构应当在医院药事管理与药物治疗学委员会(组)和医疗质量管理委员会领导下设立处方审核质量管理小组或指定专(兼)职人员,定期对机构内处方审核质量开展监测与评价,包括对信息系统审核的处方进行抽查,发现问题及时改进。

县级以上卫生健康行政部门(含中医药主管部门)可以组织或委托第三方对其核发《医疗机构执业许可证》的医疗机构处方审核质量进行检查评价。

第十七条 开展处方审核应当满足以下必备条件:

(一)配备适宜的处方审核人员;

(二)处方审核人员符合本规范第五条要求;

(三)具备处方审核场所;

(四)配备相应的处方审核工具,鼓励医疗机构建立处方审核信息系统;

(五)制订本机构的处方审核规范与制度。

第十八条 建立并实施处方审核全过程质量管理机制。

(一)审核过程追溯机制:医疗机构应当保证处方审核的全过程可以追溯,特别是针对关键流程的处理应当保存相应的记录。

(二)审核反馈机制:建立不合理处方的反馈机制,并有相应的记录。

(三)审核质量改进机制:针对处方审核,建立质量改进机制,并有相应的措施与记录。

第十九条 建立处方审核质量监测指标体系,对处方审核的数量、质量、效率和效果等进行评价。至少包括处方审核率、处方干预率、处方合理率等。

第六章 培训

第二十条 医疗机构应当组织对从事处方审核的药师进行定期培训和考核。培训内容应当包括:

(一)相关法律、法规、政策,职业道德,工作制度和岗位职责,本岗位的特殊要求及操作规程等;

(二)药学基本理论、基本知识和基本技能;从事中药处方审核的药师,还应当培训中医药基本理论、基本知识和基本技能;

(三)其他培训,如参与临床药物治疗、查房、会诊、疑难危重病例、死亡病例讨论以及临床疾病诊疗知识培训,参加院内、外举办的相关会议、学术论坛及培训班等。

第二十一条 负责处方审核的药师应当接受继续教育,不断更新、补充、拓展知识和能力,提高处方审核水平。

第七章 附则

第二十二条 不合理处方包括不规范处方、用药不适宜处方及超常处方。

第二十三条 本规范自印发之日起施行。

《关于印发医疗机构处方审核规范的通知》解读

为规范医疗机构处方审核工作,促进临床合理用药,保障患者用药安全,国家卫生健康委员会、国家中医药管理局、中央军委后勤保障部3部门联合制定了《医疗机构处方审核规范》(以下简称《规范》)。

《规范》共包括7章23条,对处方审核的基本要求、审核依据和流程、审核内容、审核质量管理、培训等作出规定。通过规范处方审核行为,一方面提高处方审核的质量和效率,促进临床合理用药;另一方面体现药师专业技术价值,转变药学服务模式,为患者提供更加优质、人性化的药学技术服务。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-09-08 jyzxjiangqin

    含中成药处方需审核。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 天地飞扬

    了解一下.谢谢分享!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2040671, encodeId=269020406e1ff, content=<a href='/topic/show?id=71924242004' target=_blank style='color:#2F92EE;'>#处方审核规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42420, encryptionId=71924242004, topicName=处方审核规范)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon Mar 18 23:24:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909249, encodeId=83fb1909249af, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 08 05:24:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942403, encodeId=3b2819424033a, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jul 18 06:24:00 CST 2018, time=2018-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343731, encodeId=b55f343e313f, content=含中成药处方需审核。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 08 14:17:04 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298483, encodeId=0279129848330, content=<a href='/topic/show?id=ac55350442f' target=_blank style='color:#2F92EE;'>#医疗机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35044, encryptionId=ac55350442f, topicName=医疗机构)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471594, encodeId=609814e15940e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545106, encodeId=82041545106dc, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554053, encodeId=d3d8155405370, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Sat Jul 14 23:24:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331380, encodeId=bc083313804e, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 13 21:02:24 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331270, encodeId=c53c3312e0df, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Jul 13 09:14:27 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 神功盖世

    0